Literature DB >> 8690162

Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion.

N H McClenaghan1, C R Barnett, E Ah-Sing, Y H Abdel-Wahab, F P O'Harte, T W Yoon, S K Swanston-Flatt, P R Flatt.   

Abstract

A novel insulin-secreting cell line (BRIN-BD11) was established after electrofusion of RINm5F cells with New England Deaconess Hospital rat pancreatic islet cells. Wells of cell fusion mixture with insulin output 5-10 times greater than parent RINm5F cells were subcultured with eventual establishment of clones, including BRIN-BD11. Morphological studies established that these cells grow as monolayers with epithelioid characteristics, maintaining stability in tissue culture for > 50 passages. Culture of these cells for 24 h at 5.6-33.3 mmol/l glucose revealed a 1.8- to 2.0-fold increase of insulin output compared with 1.4 mmol/l glucose. Dynamic insulin release was recorded in response to 16.7 mmol/l glucose, resulting in a rapid threefold insulin secretory peak followed by a sustained output slightly above basal. In acute 20-min tests, 4.2-16.7 mmol/l glucose evoked a stepwise two- to three-fold stimulation of insulin release. 3-Isobutyl-1-methylxanthine (1 mmol/l) served to increase basal and glucose-stimulated insulin release, shifting the threshold from 4.4 to 1.1 mmol/l glucose. Stimulation of insulin secretion with 16.7 mmol/l glucose was abolished by mannoheptulose or diazoxide (15 or 0.5 mmol/l). In contrast, glyceraldehyde (10 mmol/l) and 25 mmol/l K+ evoked 1.7- to 9.0-fold insulin responses. L-Alanine (10 mmol/l) evoked a twofold secretory response, which was potentiated 1.4-fold by increasing the Ca2+ concentration from 1.28 to 7.68 mmol/l. Forskolin (25 mumol/l) and phorbol 12-myristate 13-acetate (10 nmol/l) both increased insulin secretion in the presence of L-alanine (1.4- and 1.8-fold, respectively). Western blotting confirmed that BRIN-BD11 cells expressed the GLUT2 glucose transporter. This, coupled with a high glucokinase/hexokinase ratio in the cells, confirms an intact glucose sensing mechanism. High-performance liquid chromatography analysis demonstrated that insulin was the major product secreted under stimulatory conditions. Collectively, these data indicate that the BRIN-BD11 cell line represents an important stable glucose-responsive insulin-secreting beta-cell line for future studies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8690162     DOI: 10.2337/diab.45.8.1132

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  45 in total

1.  Development and functional characterization of insulin-releasing human pancreatic beta cell lines produced by electrofusion.

Authors:  Jane T McCluskey; Muhajir Hamid; Hong Guo-Parke; Neville H McClenaghan; Ramon Gomis; Peter R Flatt
Journal:  J Biol Chem       Date:  2011-04-22       Impact factor: 5.157

2.  Evaluation of the insulin releasing and antihyperglycaemic activities of GPR55 lipid agonists using clonal beta-cells, isolated pancreatic islets and mice.

Authors:  A M McKillop; B M Moran; Y H A Abdel-Wahab; P R Flatt
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

3.  miR-25 and miR-92a regulate insulin I biosynthesis in rats.

Authors:  Dwi Setyowati Karolina; Sugunavathi Sepramaniam; Hui Zhing Tan; Arunmozhiarasi Armugam; Kandiah Jeyaseelan
Journal:  RNA Biol       Date:  2013-08       Impact factor: 4.652

4.  Schizandra arisanensis extract attenuates cytokine-mediated cytotoxicity in insulin-secreting cells.

Authors:  Yi-Shin Hsu; Yao-Haur Kuo; Hui-Ling Cheng; Peter R Flatt; Hui-Kang Liu
Journal:  World J Gastroenterol       Date:  2012-12-14       Impact factor: 5.742

5.  Beneficial effects of the novel cholecystokinin agonist (pGlu-Gln)-CCK-8 in mouse models of obesity/diabetes.

Authors:  N Irwin; P Frizelle; I A Montgomery; R C Moffett; F P M O'Harte; P R Flatt
Journal:  Diabetologia       Date:  2012-07-20       Impact factor: 10.122

6.  Cystine accumulation attenuates insulin release from the pancreatic β-cell due to elevated oxidative stress and decreased ATP levels.

Authors:  Bernadette McEvoy; Rodolfo Sumayao; Craig Slattery; Tara McMorrow; Philip Newsholme
Journal:  J Physiol       Date:  2015-11-18       Impact factor: 5.182

7.  Streptozotocin-resistant BRIN-BD11 cells possess wide spectrum of toxin tolerance and enhanced insulin-secretory capacity.

Authors:  Hui-Kang Liu; Jane T McCluskey; Neville H McClenghan; Peter R Flatt
Journal:  Endocrine       Date:  2007-09-29       Impact factor: 3.633

8.  Structural requirements for the cytoprotective actions of mono-unsaturated fatty acids in the pancreatic beta-cell line, BRIN-BD11.

Authors:  S Dhayal; H J Welters; N G Morgan
Journal:  Br J Pharmacol       Date:  2008-02-25       Impact factor: 8.739

9.  A novel DPP IV-resistant C-terminally extended glucagon analogue exhibits weight-lowering and diabetes-protective effects in high-fat-fed mice mediated through glucagon and GLP-1 receptor activation.

Authors:  Aisling M Lynch; Nupur Pathak; Varun Pathak; Finbarr P M O'Harte; Peter R Flatt; Nigel Irwin; Victor A Gault
Journal:  Diabetologia       Date:  2014-06-25       Impact factor: 10.122

10.  Overexpression of the malate-aspartate NADH shuttle member Aralar1 in the clonal beta-cell line BRIN-BD11 enhances amino-acid-stimulated insulin secretion and cell metabolism.

Authors:  Katrin Bender; Pierre Maechler; Neville H McClenaghan; Peter R Flatt; Philip Newsholme
Journal:  Clin Sci (Lond)       Date:  2009-09-01       Impact factor: 6.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.